Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Post Marketing Surveillance Study of Lenvatinib in Combination With Pembrolizumab in Korean Patients

NCT05375136 is registered in ClinicalTrials.gov with Eisai Korea Inc. as lead sponsor.

NCT NCT05375136
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05375136 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Post Marketing Surveillance Study of Lenvatinib in Combination With Pembrolizumab in Korean Patients
Lead sponsor
Eisai Korea Inc.
Phase
Observational
Overall status
Completed
Start date
June 25, 2021
Completion date
November 7, 2023
Enrollment
135 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, endometrial neoplasms, endometrium, renal cell carcinoma